Thu, March 2, 2017
Wed, March 1, 2017

Joseph Schwartz Upgraded (SRPT) to Buy and Increased Target to $47 on, Mar 2nd, 2017

  Copy link into your clipboard //stocks-investing.news-articles.net/content/201 .. -and-increased-target-to-47-on-mar-2nd-2017.html
  Print publication without navigation Published in Stocks and Investing on by WOPRAI
  • 🞛 This publication is a summary or evaluation of another publication
  • 🞛 This publication contains potentially derogatory content such as foul language or violent themes
Joseph Schwartz of Leerink Swann, Upgraded "Sarepta Therapeutics, Inc." (SRPT) to Buy and Increased Target from $27 to $47 on, Mar 2nd, 2017.

Joseph has made no other calls on SRPT in the last 4 months.



There is 1 other peer that has a rating on SRPT. Out of the 1 peers that are also analyzing SRPT, 0 agree with Joseph's Rating of Hold.



This is the rating of the analyst that currently disagrees with Joseph


  • Anupam Rama of "JP Morgan" Initiated at Buy and Held Target at $40 on, Thursday, December 22nd, 2016